Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 19/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 19/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377640 | 1.00 | CDK2 (0.56) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4372328 | 0.87 | FLT3 (0.55) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4372495 | 0.87 | FLT3 (0.55) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4374864 | 0.85 | FLT3 (0.43) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4374861 | 0.85 | FLT3 (0.43) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4372901 | 0.83 | CDK2 (0.54) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4372906 | 0.83 | CDK2 (0.54) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL4373952 | 0.80 | CDK2 (0.49) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL30848442 | 0.79 | CCNE2 (0.73) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL30848443 | 0.79 | CCNE2 (0.73) | CDK2CCNE2CCNA2CCNE1CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7429595-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-6861524-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040248908-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1377579-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Aventis Pharmaceuticals Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTISUB LLC | 2003-04-10 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | BAD, BAX, MCL1 | CDK2 167/4885CCNE2 2100/4885CCNA2 233/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | CDK2 2629/4885CCNE2 4357/4885CCNA2 3888/4885 |
| US-20040248908-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | TYMP, TK1, SLC29A1 | CDK2 68/4885CCNE2 697/4885CCNA2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.